Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Otena still in the game

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Mar 31, 2022 4:17pm

206 Views

Post# 34564505

RE:RE:RE:Otena still in the game

woundedknee wrote: This is all fine if you are a 30 or 40 year shareholder. I don't even think Dan will live long enough to see this a post op pain killer. lol

Dan just wants to see it going to P3 without liver confusion - then he can sell it.
Hope we can get the dosing right going into P2 - much easier than with chronic (you'd think).

Also - would be really good to have chronic figured out by the time we negotiate.
Hoping a much higher dose and less frequency (less than daily) will do the trick !!!

Fingers crossed that it all comes together.

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks